OK, fair enough, then tell us which projected PPS you trust, because a inferior drug to MANF, GDNF was bought for $270 million several years back? Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI). Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases where MANF is currently being evaluated.
How reliable is this source that recently upgraded AMBS with a 2.25 target by the fall of this year? The bios of the blog writers states the one guy used to write for Sierra Equity, which everyone knows is a complete joke.
Personally, I find this target hard to take seriously. Seems like an amateur blog and these guys just threw out a random price target based on nothing.
Market Data 
Markets 
AI
